Financials

Discussions Technicals Seasonals

6564 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Enimmune Corp. engages in the research, development of new drugs. Its products include EV71, Japanese encephalitis virus, EV71+CA16 bivalent, tetanus toxoid adsorbed, influenza, AH1N1, and pneumococcal vaccines. The company operates pharmaceutical outlets. Enimmune was founded on January 10, 2014 and is headquartered in Taipei, Taiwan.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

6564 has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company